MKI67 and intestinal neuroendocrine neoplasm: Lanreotide significantly prolonged PFS in a large population with advanced grade 1 or 2 (Ki-67 up to 10%) pancreatic and intestinal NETs and indolent disease (96% SD according to RECIST), irrespective of hepatic tumour load; median PFS for lanreotide was not reached (Caplin et al. 2014).